Cargando…
Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation
OBJECTIVE: To assess the pharmacokinetics and safety of liquid palivizumab compared with lyophilized palivizumab. METHODS: This phase 2, randomized, double-blind crossover study included premature infants aged ≤6 months born ≤35 weeks gestational age. Patients were randomized in a 1:1 ratio to recei...
Autores principales: | Robbie, Gabriel J., Makari, Doris, Harris, Brian, Losonsky, Genevieve A., Jafri, Hasan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269619/ https://www.ncbi.nlm.nih.gov/pubmed/25269648 http://dx.doi.org/10.1007/s40121-014-0042-x |
Ejemplares similares
-
Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity
por: Makari, Doris, et al.
Publicado: (2014) -
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
por: Fernández, Pilar, et al.
Publicado: (2010) -
Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019) -
P386: COMPARISON OF THE PHARMACOKINETICS OF THE LIQUID AND THE LYOPHILIZED FORMULATIONS OF PEGASPARGASE IN THE TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
por: Karachunskiy, Alexander, et al.
Publicado: (2023) -
Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging
por: Franzé, Silvia, et al.
Publicado: (2018)